Truist lowered the firm’s price target on Ultragenyx (RARE) to $100 from $140 and keeps a Buy rating on the shares. The company’s Q1 results were in-line and the management reiterated its FY25 revenue guidance, though the firm’s price target is cut on tampered outlook for gene therapy programs, the analyst tells investors in a research note.
Protect Your Portfolio Against Market Uncertainty
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RARE:
Disclaimer & DisclosureReport an Issue
